Century Therapeutics, Inc. (NASDAQ:IPSC) Insider Gregory Russotti Sells 5,000 Shares

Century Therapeutics, Inc. (NASDAQ:IPSC) insider Gregory Russotti sold 5,000 shares of the stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $3.12, for a total transaction of $15,600.00. Following the sale, the insider now owns 292,319 shares in the company, valued at $912,035.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Gregory Russotti also recently made the following trade(s):

• On Monday, April 22nd, Gregory Russotti sold 5,000 shares of Century Therapeutics stock. The shares were sold at an average price of $3.10, for a total transaction of $15,500.00.

Century Therapeutics Stock Up 6.3 %

NASDAQ IPSC opened at $3.37 on Wednesday. Century Therapeutics, Inc. has a 52 week low of $1.28 and a 52 week high of $5.51. The business has a 50 day moving average price of $3.90 and a 200-day moving average price of $3.22. The company has a market cap of $218.44 million, a price-to-earnings ratio of -1.47 and a beta of 1.44.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.07. Century Therapeutics had a negative net margin of 6,115.12% and a negative return on equity of 54.73%. The business had revenue of $0.27 million during the quarter, compared to analyst estimates of $1.69 million. On average, equities research analysts anticipate that Century Therapeutics, Inc. will post -1.94 earnings per share for the current year.

Hedge Funds Weigh In On Century Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Abel Hall LLC bought a new stake in shares of Century Therapeutics in the 4th quarter worth $33,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Century Therapeutics during the first quarter worth about $47,000. Federated Hermes Inc. grew its position in Century Therapeutics by 0.4% in the 4th quarter. Federated Hermes Inc. now owns 618,482 shares of the company’s stock worth $2,053,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Avidity Partners Management LP increased its stake in Century Therapeutics by 23.4% in the 4th quarter. Avidity Partners Management LP now owns 1,355,000 shares of the company’s stock valued at $4,499,000 after buying an additional 256,500 shares during the last quarter. Institutional investors own 50.20% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on IPSC shares. Canaccord Genuity Group lifted their price objective on Century Therapeutics from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Century Therapeutics in a report on Friday, March 15th. Finally, Piper Sandler restated an “overweight” rating and set a $9.00 price target (down from $10.00) on shares of Century Therapeutics in a report on Friday, April 12th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $13.60.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.